Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cyclopharm Limited ( (AU:CYC) ) has shared an update.
Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, lifting its global footprint to 67 countries and reinforcing its position in functional lung ventilation imaging. The move supports the company’s strategy to broaden access to low-radiation, high-resolution functional ventilation imaging that can be integrated with AI-enabled platforms for precise measurement of regional lung function. With Technegas now expanding into wider respiratory applications, including COPD, asthma, lung transplantation and oncologic planning, the Colombian approval is strategically timed ahead of the World Federation of Nuclear Medicine and Biology Congress in Cartagena in early 2026, providing a high-profile venue to showcase the technology and accelerate clinical adoption in partnership with local centres, which could further entrench Cyclopharm’s standing among nuclear medicine specialists globally.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.97 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company focused on nuclear medicine, best known for its core product Technegas, a proprietary ultra-fine radioactive carbon dispersion used for functional lung ventilation imaging. Technegas is widely used in the diagnosis of pulmonary embolism and, supported by extensive clinical evidence and millions of patient procedures, is increasingly applied to broader respiratory indications such as COPD, asthma, pulmonary hypertension, lung transplantation, and pre-surgical and radiotherapy planning, positioning Cyclopharm in the global functional lung imaging market.
Average Trading Volume: 82,879
Technical Sentiment Signal: Sell
Current Market Cap: A$105.6M
See more data about CYC stock on TipRanks’ Stock Analysis page.